Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type

Erlotinib is one of the treatment choices for patients with advanced non-small cell lung cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status. However, its efficacy for the treatment of patients with NSCLC with EGFR wild type or who are beyond the usage of gefiti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncol Lett
Main Authors: Hirai, Fumihiko, Edagawa, Makoto, Shimamatsu, Shinichiro, Toyozawa, Ryo, Toyokawa, Gouji, Nosaki, Kaname, Yamaguchi, Masafumi, Seto, Takashi, Takenoyama, Mitsuhiro, Ichinose, Yukito
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494899/
https://ncbi.nlm.nih.gov/pubmed/28693169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6118
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados